| Predicting breast cancer by applying deep learning to linked health records and mammograms A Akselrod-Ballin, M Chorev, Y Shoshan, A Spiro, A Hazan, R Melamed, ... Radiology 292 (2), 331-342, 2019 | 157 | 2019 |
| Screening human embryos for polygenic traits has limited utility E Karavani, O Zuk, D Zeevi, N Barzilai, NC Stefanis, A Hatzimanolis, ... Cell 179 (6), 1424-1435. e8, 2019 | 106 | 2019 |
| Benchmarking framework for performance-evaluation of causal inference analysis Y Shimoni, C Yanover, E Karavani, Y Goldschmnidt arXiv preprint arXiv:1802.05046, 2018 | 44 | 2018 |
| In vivo cleavage rules and target repertoire of RNase III in Escherichia coli Y Altuvia, A Bar, N Reiss, E Karavani, L Argaman, H Margalit Nucleic acids research 46 (19), 10380-10394, 2018 | 43 | 2018 |
| An evaluation toolkit to guide model selection and cohort definition in causal inference Y Shimoni, E Karavani, S Ravid, P Bak, TH Ng, SH Alford, D Meade, ... arXiv preprint arXiv:1906.00442, 2019 | 33 | 2019 |
| Causalvis: Visualizations for causal inference G Guo, E Karavani, A Endert, BC Kwon Proceedings of the 2023 CHI conference on human factors in computing systems …, 2023 | 10 | 2023 |
| Propensity score models are better when post-calibrated R Gutman, E Karavani, Y Shimoni arXiv preprint arXiv:2211.01221, 2022 | 4 | 2022 |
| FairPRS: adjusting for admixed populations in polygenic risk scores using invariant risk minimization D Machado Reyes, A Bose, E Karavani, L Parida PACIFIC SYMPOSIUM ON BIOCOMPUTING 2023: Kohala Coast, Hawaii, USA, 3–7 …, 2023 | 3* | 2023 |
| A discriminative approach for finding and characterizing positivity violations using decision trees E Karavani, P Bak, Y Shimoni arXiv preprint arXiv:1907.08127, 2019 | 3 | 2019 |
| Comment: causal inference competitions: where should we aim? E Karavani, T El-Hay, Y Shimoni, C Yanover | 2 | 2019 |
| Distributed anonymous scoring technique Y Shimoni, E Karavani, S Ravid, MY Ninio, R Melamed US Patent 11,563,576, 2023 | 1 | 2023 |
| Detecting positivity violations in multidimensional data P Bak, E Karavani, Y Shimoni US Patent 11,354,297, 2022 | 1 | 2022 |
| Improving Inverse Probability Weighting by Post-calibrating Its Propensity Scores R Gutman, E Karavani, Y Shimoni Epidemiology, 10.1097, 2024 | | 2024 |
| Hierarchical Bias-Driven Stratification for Interpretable Causal Effect Estimation L Ter-Minassian, L Szlak, E Karavani, C Holmes, Y Shimoni arXiv preprint arXiv:2401.17737, 2024 | | 2024 |
| Trends in clinical characteristics and associations of severe non-respiratory events related to SARS-CoV-2 T El-Hay, E Karavani, A Peretz, M Ninio, S Ravid, M Chorev, M Rosen-Zvi, ... medRxiv, 2021.03. 24.21251900, 2021 | | 2021 |
| RW3 FRAMEWORK FOR RELIABLE VALUE ASSESSMENT OF TREATMENTS USING CAUSAL ANALYSIS OF OBSERVATIONAL DATA: SUPPORT MATCHING BIOLOGICAL THERAPY TO RHEUMATOID ARTHRITIS PATIENTS Y Shimoni, S Ravid, P Bak, E Karavani, SH Alford, D Meade, ... Value in Health 22, S389, 2019 | | 2019 |
| SA51THE LIMITS OF POLYGENIC EMBRYO SELECTION FOR COGNITIVE ABILITY T Lencz, E Karavani, M Lam, N Barzilai, N Stefanis, A Hatzimanolis, ... European Neuropsychopharmacology 29, S1215-S1216, 2019 | | 2019 |
| The Limits of Polygenic Embryo Selection for Cognitive Ability T Lencz, E Karavani, M Lam, N Barzilai, N Stefanis, A Hatzimanolis, ... NEUROPSYCHOPHARMACOLOGY 43, S319-S319, 2018 | | 2018 |
| Single-Microglia Transcriptomic Transition Network-Based Prediction and Real-World Patient Data Validation Identifies Ketorolac as a Repurposable Drug for Alzheimer's Disease J Xu, M Danziger, Z Wu, C Zang, Y Zhou, Y Hou, E Karavani, Y Shimoni, ... | | |
